In one paragraphArticle in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
9 authors.
Rositsa MihaylovaDepartment of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, 1000 Sofia, Bulgaria.ORCID 0000-0001-5763-0730 Nikolay BebrivenskiDepartment of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, 1000 Sofia, Bulgaria.
Dimitrina Zheleva-DimitrovaDepartment of Pharmacognosy, Faculty of Pharmacy, Medical University of Sofia, 1000 Sofia, Bulgaria.ORCID 0000-0002-1952-9903 Rumyana SimeonovaDepartment of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, 1000 Sofia, Bulgaria.ORCID 0000-0003-4860-9053 Vesela LozanovaDepartment of Medical Chemistry and Biochemistry, Faculty of Medicine, Medical University-Sofia, 1000 Sofia, Bulgaria.ORCID 0000-0002-7748-4133 Ralitza AlexovaDepartment of Medical Chemistry and Biochemistry, Faculty of Medicine, Medical University-Sofia, 1000 Sofia, Bulgaria.
Vanyo MitevDepartment of Medical Chemistry and Biochemistry, Faculty of Medicine, Medical University-Sofia, 1000 Sofia, Bulgaria.ORCID 0000-0001-7528-590X Reneta GevrenovaDepartment of Pharmacognosy, Faculty of Pharmacy, Medical University of Sofia, 1000 Sofia, Bulgaria.ORCID 0000-0002-1254-2419 Georgi MomekovDepartment of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University of Sofia, 1000 Sofia, Bulgaria.ORCID 0000-0003-2841-7089 Funding
European Union's NextGenerationEU economic recovery package via the National Recovery and Resilience Plan of the Republic of Bulgaria, project No. BG-RRP-2.004-0004-C01 European Union's NextGenerationEU economic recovery package via the National Recovery and Resilience Plan of the Republic of Bulgaria, project No. BG-RRP-2.004-0004-C01.
6 · The paper itselfAbstract
Resistance to apoptosis represents a major limitation of platinum-based chemotherapy in colorectal carcinoma, frequently arising from impaired p53 signaling and inefficient execution of programmed cell death. In this study, we investigated the anticancer activity of
Indexed as
ApoptosisCaspase 3CisplatinColorectal NeoplasmsEricaceaePlant ExtractsTumor Suppressor Protein p53Antineoplastic AgentsCell Line, TumorCell SurvivalDrug SynergismHT29 CellsHumansAntineoplastic AgentsCaspase 3CisplatinPlant ExtractsTP53 protein, humanTumor Suppressor Protein p53caspase-3Chou–Talalay methodcisplatincolorectal carcinomadrug resistanceErica spiculifoliap53synergism
Identifiers
PMID41752487
PMCPMC12943122
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390